ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combination improves treatment response. About 50 adults will take p…
Matched conditions: ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 06:20 UTC
-
New Triple-Drug attack shows promise against tough lymphomas
Disease control OngoingThis study tests a new drug combination (ALX148, rituximab, and lenalidomide) in people with slow-growing or fast-growing B-cell non-Hodgkin lymphoma that has not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink or eliminate tumors. …
Matched conditions: ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC